Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry

European Journal of Preventive Cardiology

Volumn 23, Issue 4, 2016, Pages 340-348

  Hambraeus, Kristina ^a,b   Tydén, Patrik ^c   Lindahl, Bertil ^b,d  

^a FALUN HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Guideline adherence; myocardial infarction; registry study; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASUGREL; TICAGRELOR; TRIACYLGLYCEROL; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EVIDENCE BASED PRACTICE; EXERCISE; FEMALE; HEART REHABILITATION; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TIME TO TREATMENT; TREATMENT DURATION; BLOOD; HEALTH BEHAVIOR; HYPERTENSION; MEDICATION COMPLIANCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROTOCOL COMPLIANCE; REGISTER; SEX RATIO; STATISTICS AND NUMERICAL DATA; SWEDEN;

AGED; CARDIOVASCULAR AGENTS; CHOLESTEROL, LDL; FEMALE; GUIDELINE ADHERENCE; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT READMISSION; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; SECONDARY PREVENTION; SEX DISTRIBUTION; SEX FACTORS; SMOKING CESSATION; SWEDEN;

EID: 84957571169     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315585293     Document Type: Article

References (32)

1. Hahn J, Lessard D, Yarzebski J, et al. A community-wide perspective into changing trends in the utilization of diagnostic and interventional procedures in patients hospitalized with acute myocardial infarction. Am Heart J 2007; 153: 594-605.
2. Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305: 1677-1684.
3. Buch P, Rasmussen S, Gislason GH, et al. Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart 2007; 93: 210-215.
4. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755-2764.
5. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): S1-113.
6. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372.
7. Members: ATF, Perk J, De Backer G, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-1701.
8. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
9. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006; 295: 1912-1920.
10. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940.
11. Vedin O, Hagstrom E, Stewart R, et al. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: Baseline results from the STABILITY study. Eur J Preventive Cardiol 2013; 20: 678-685.
12. Colella TJ, Gravely S, Marzolini S, et al. Sex bias in referral of women to outpatient cardiac rehabilitation? A meta-analysis. Eur J Preventive Cardiol 2015; 22 (4): 423-441.
13. Cooney MT, Kotseva K, Dudina A, et al. Determinants of risk factor control in subjects with coronary heart disease: A report from the EUROASPIRE III investigators. Eur J Preventive Cardiol 2013; 20: 686-691.
14. Lawesson SS, Alfredsson J, Fredrikson M, et al. Time trends in STEMI-improved treatment and outcome but still a gender gap: A prospective observational cohort study from the SWEDEHEART register. BMJ open 2012; 2: e000726-e000726.
15. Lauffenburger JC, Robinson JG, Oramasionwu C, et al. Racial/ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation 2014; 129: 754-763.
16. Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart 2010; 96: 1617-1621.
17. Brown JR, Conley SM, Niles NW 2nd,. Predicting readmission or death after acute ST-elevation myocardial infarction. Clin Cardiol 2013; 36: 570-575.
18. Kociol RD, Lopes RD, Clare R, et al. International variation in and factors associated with hospital readmission after myocardial infarction. JAMA 2012; 307: 66-74.
19. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015. Epub ahead of print 13 January 2015. DOI: 10.1093/eurheartj/ehu505.
20. Wilson PW, D'Agostino R Sr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med 2012; 125: 695-703.
21. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121-137.
22. Hambraeus K, Lindhagen L, Tyden P, et al. Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden. Am J Cardiol 2014; 113: 17-22.
23. Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res 2007; 55: 81-95.
24. Nguyen TN, Abramson BL, Galluzzi A, et al. Temporal trends and referral factors for cardiac rehabilitation post-acute coronary syndrome in ontario: Insights from the Canadian Global Registry of Acute Coronary Events. Can J Cardiol 2013; 29: 1604-1609.
25. Goel K, Lennon RJ, Tilbury RT, et al. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation 2011; 123: 2344-2352.
26. (Anonymous) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708-715.
27. Chan WC, Wright C, Tobias M, et al. Explaining trends in coronary heart disease hospitalisations in New Zealand: Trend for admissions and incidence can be in opposite directions. Heart 2008; 94: 1589-1593.
28. Gulliksson M, Wedel H, Koster M, et al. Hazard function and secular trends in the risk of recurrent acute myocardial infarction: 30 years of follow-up of more than 775,000 incidents. Circ Cardiovasc Qual Outcomes 2009; 2: 178-185.
29. Hoekstra JW, Pollack CV Jr, Roe MT, et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med 2002; 9: 1146-1155.
30. Mehta RH, Roe MT, Chen AY, et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: Insights from the CRUSADE initiative. Archiv Internal Med 2006; 166: 2027-2034.
31. Carlhed R, Bojestig M, Wallentin L, et al. Improved adherence to Swedish national guidelines for acute myocardial infarction: The Quality Improvement in Coronary Care (QUICC) study. Am Heart J 2006; 152: 1175-1181.
32. http://www.ucr.uu.se/swedeheart/index.php/component/docman/doc-download/345-swedeheart-arsrapport-2013-english, 2013 (cited 15 February 2015).